Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00207051 · ClinicalTrials.gov registry record · Phase 1
BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT00207051 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 62 participants.
The verdict
NCT00207051, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is a phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in combination with full dose erbitux in patients with advanced colorectal cancer who have received no more than 2 prior regimens for metastatic colorectal cancer.
Interventions
- DRUG Brivanib + Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00207051
The ClinicalTrials.gov registry entry for NCT00207051 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brivanib + Cetuximab is the first listed.
NCT00207051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00207051 about?
NCT00207051 is a clinical study titled "BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies". This is a phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in combination with full dose erbitux in patients with advanced colorectal cancer who have received no more than 2 prior regimens for metastatic colorectal cancer.
What is the current status of trial NCT00207051?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2006-01. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00207051?
The interventions under investigation include: Brivanib + Cetuximab (DRUG).
Who is sponsoring clinical trial NCT00207051?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.